社團法人臺灣臨床藥學會

已出刊文章

【案例報告】Linezolid引起的貧血及血小板減少症-案例報告
Linezolid-Induced Anemia and Thrombocytopenia - A Adverse Drug Reaction Case Report
骨髓炎、感染性脊椎炎、 linezolid、血小板減少症、貧血、osteomyelitis, infectious spondylitis, linezolid, thrombocytopenia, anemia
蕭旋玲Hsuan-Ling Hsiao1 、蔡春玉Chun-Yu Tsai*2,3
1長庚紀念醫院 藥劑部 、2長庚紀念醫院 行政中心藥劑部 、3台北學大學 藥學系
Linezolid 是屬於 oxazolidinone 類之抗生素,在格蘭氏陽性菌感染症扮演後線治療之角色,其特殊的藥動學性質為慢性骨髓炎在治療上提供新的選擇。副作用方面以腸胃道較常見,而使用療程大於 2 週以上則必須注意對血液學方面的影響。本文報告一名感染性脊椎炎病患在使用linezolid數週後發生的血液學變化及其評估的方式,建議定期監測血液學變化及病患臨床狀態,以達到最佳臨床療效並確保病患用藥安全。

Linezolid, an oxazolidinone antibiotic, is the first representative of a truly novel class and efficacious in serious or problematic infections for which there are few therapeutic alternatives. The intrinsic properties of linezolid make it an attractive candidate for the treatment of chronic osteomyelitis. Although generally well tolerated, gastrointestinal adverse effects are relatively common and thrombocytopenia and a slight increased risk for anemia were evident at ≧ 2 weeks of linezolid therapy. We report a case with hematologic abnormalities were consistent with reversible, duration-dependent event. Appropriate weekly hematologic monitoring is warranted with linezolid therapy.

 
操作進行中,請稍候~~~~
×
加载中...